AgomAb Therapeutics (NASDAQ:AGMB) Now Covered by B. Riley Financial

B. Riley Financial assumed coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research report released on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $34.00 price objective on the stock.

Separately, HC Wainwright started coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, AgomAb Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $33.00.

AgomAb Therapeutics Stock Performance

Shares of AGMB stock opened at $12.97 on Thursday. The business’s 50 day moving average is $11.75. AgomAb Therapeutics has a 52 week low of $8.75 and a 52 week high of $17.82.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.